Background The objective of this study was to evaluate the efficacy and toxicity of gefitinib as
a first-line therapy in patients with advanced non-small cell lung cancer (NSCLC). Methods …

Most patients with non-small-cell lung cancer (NSCLC) present with advanced disease and
their long-term prognosis remains poor, even after platinum-based chemotherapy. EGF …

The aim of this study was to evaluate the efficacy and safety of gefitinib as a first-line therapy
for advanced non-small cell lung cancer (NSCLC). Patients with advanced NSCLC who did …

PURPOSE: This phase II single arm, open label study was designed to evaluate the efficacy
and toxicity of oral gefitinib (250mg) daily in previously untreated patients with advanced …

Objective To evaluate the efficacy and safety of gefitinib for the treatment of advanced non-
small cell lung cancer (NSCLC). Methods 125 patients with advanced NSCLC who had …

Objective To evaluate the safety and efficacy of gefitinib as second-line or even third-line
treatment for previously treated patients with locally advanced or metastatic non-small cell …

OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and toxicity of
gefitinib in non–small-cell lung cancer (NSCLC). DATA SOURCES: Primary literature search …

Objective To investigate the efficacy, time to progression, survival time and toxicity of
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor Gefitinib (Iressa), a target …

Objective To observe the efficacy, median survival time, time to progression, quality of life
and adverse effect of gefitinib (IRESSA) in the treatment for refractory advanced non-small …

Background and purpose Gefitinib is effective in the treatment of advanced non-small cell
lung cancer (NSCLC). However, most studies have only investigated patients who have …